Abstract:Background: Pulmonary arterial hypertension (PAH) is a progressive proliferative vasculopathy associated with mechanical and electrical changes, culminating in increased vascular resistance, right ventricular (RV) failure, and death. With a main focus on invasive tools, there has been an underutilization of echocardiography, electrocardiography, and biomarkers to non-invasively assess the changes in myocardial and pulmonary vascular structure and function during the course of PAH. Methods: A SU5416-hypoxia rat model was used for inducing PAH. Biventricular functions were measured using transthoracic two-dimensional (2D) echocardiography/Doppler (echo/Doppler) at disease onset (0 week), during progression (3 weeks), and establishment (5 weeks). Similarly, electrocardiography was performed at 0, 3, and 5 weeks. Invasive hemodynamic measurements and markers of cardiac injury in plasma were assessed at 0, 3, and 5 weeks. Results: Increased RV systolic pressure (RVSP) and rate of isovolumic pressure rise and decline were observed at 0, 3, and 5 weeks in PAH animals. EKG showed a steady increase in QT-interval with progression of PAH, whereas P-wave height and RS width were increased only during the initial stages of PAH progression. Echocardiographic markers of PAH progression and severity were also identified. Three echocardiographic patterns were observed: a steady pattern (0–5 weeks) in which echo parameter changed progressively with severity [inferior vena cava (IVC) expiratory diameter and pulmonary artery acceleration time (PAAT)], an early pattern (0–3 weeks) where there is an early change in parameters [RV fractional area change (RV-FAC), transmitral flow, left ventricle (LV) output, estimated mean PA pressure, RV performance index, and LV systolic eccentricity index], and a late pattern (3–5 weeks) in which there is only a late rise at advanced stages of PAH (LV diastolic eccentricity index). RVSP correlated with PAAT, PAAT/PA ejection times, IVC diameters, RV-FAC, tricuspid systolic excursion, LV systolic eccentricity and output, and transmitral flow. Plasma myosin light chain (Myl-3) and cardiac troponin I (cTnI) increased progressively across the three time points. Cardiac troponin T (cTnT) and fatty acid-binding protein-3 (FABP-3) were significantly elevated only at the 5-week time point. Conclusion: Distinct electrocardiographic and echocardiographic patterns along with plasma biomarkers were identified as useful non-invasive tools for monitoring PAH progression.

Therapeutic Monitoring Response of Pulmonary Arterial Hypertension Using a Combined Computed Tomography- Computational Fluid Analysis Strategy.

Tissue Doppler Imaging Study of Right Ventricular Myocardial Systolic Activation in Subjects with Pulmonary Arterial Hypertension

Patient-Specific Computational Analysis of Hemodynamics and Wall Mechanics and Their Interactions in Pulmonary Arterial Hypertension

3D Vortex‐Energetics in the Left Pulmonary Artery for Differentiating Pulmonary Arterial Hypertension and Pulmonary Venous Hypertension Groups Using 4D Flow MRI

[Pharmacological studies of luohanguo yanhou tablet].

Multidimensional CT approach to predict hemodynamics in pulmonary hypertension.

Circulating Biomarkers in Pulmonary Arterial Hypertension: An Update

Patient-Specific Computational Analysis of Ventricular Mechanics in Pulmonary Arterial Hypertension

[Flow Simulation of Normal Pulmonary Artery Branches Based on CT Image].

Self-Supplied Nano-Fusing and Transferring Metal Nanostructures via Surface Oxide Reduction.

Medical Image-Based Hemodynamic Analyses in a Study of the Pulmonary Artery in Children With Pulmonary Hypertension Related to Congenital Heart Disease

Quantitative evaluation of pulmonary hypertension using 4D flow MRI: A retrospective study

Hemodynamic measurement in pulmonary hypertension: a challenge for automated CT analysis

Echocardiographic, Biochemical, and Electrocardiographic Correlates Associated With Progressive Pulmonary Arterial Hypertension

Computational Fluid Dynamics Modeling of the Human Pulmonary Arteries with Experimental Validation

Diagnosis and Treatment of Pulmonary Arterial Hypertension: A Review.

Echocardiography in Pulmonary Arterial Hypertension: Comprehensive Evaluation and Technical Considerations

Medical Management of Pulmonary Arterial Hypertension: Current Approaches and Investigational Drugs

[The effect of Sabin virus on the metabolism of HeLa cells. II. Respiration and glycolysis of HeLa cells infected with Sabin virus].

Non-Invasive Assessment of Endothelial Dysfunction in Pulmonary Arterial Hypertension

Early detection and treatment of connective tissue disease associated pulmonary arterial hypertension